\
&
Contact us
\
&
Contact us
This was 1 month ago
LocationBrussels
The European Innovation Council (EIC) kindly invites you to its Info Day about the EIC Pathfinder Challenges, published in the EIC 2025 Work Programme. The Info Day takes place in Brussels on Friday, 4 April 2025, right after the EIC Summit 2025. It consists of a plenary session explaining the specific characteristics of EIC Pathfinder Challenge calls, and parallel sessions by the EIC Programme Managers Ivan Stefanic, Federica Zanca, Franc Mouwen and Carina Faber. Please see the agenda below.
All parts of the Info Day will be livestreamed and recorded. Recordings and slides will be made available for the public after the Info Day. Remote participants can participate in the discussions and Q&A by submitting their questions via sli.do. For general questions, you are invited to consult the EIC Pathfinder FAQ website.
To participate in person to the Info Day, please register here by 25 March.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Climate, Energy, Mobility EIC EIE
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
